Study Shows Drugs Have Comparable Residual Effects
The newer, short-acting, nonbenzodiazepine hypnotic drugs,such as zolpidem, have been touted because of their apparentlyreduced daytime residual effects, compared with other insomniadrugs. Finnish scientists determined zolpidem and the benzodiazepinesleep agent temazepam, however, to be equal intheir next-day residual effects on certain psychomotor activities.
A double-blind, randomized, placebo-controlled study, publishedin Sleep Medicine (November 2003), compared the earlymorningdriving ability of women who had taken zolpidem ortemazepam at 2 AM. Five and a half hours after dosing, therewere no significant differences in almost all measures of thepatients' driving ability, when compared with placebo.
Interestingly, the patients who were administered zolpidemhad more difficulty maintaining proper lane position, comparedwith the temazepam and placebo groups. The study also highlightedthe varied patient susceptibility to the effects of thedrugs—an important consideration when evaluating individualtreatment options for insomnia.
Articles in this issue
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Related Articles
- Advise Patients About Self-Care Measures to Treat Mild to Moderate GI Issues
September 18th 2025
- Evaluation of Pharmacist-Driven Penicillin Allergy Reconciliation
September 17th 2025
- Pharmacists Can Apply Their Expertise to the Medical Psilocybin Act
September 16th 2025
- From Curiosity to Clinical Impact: Shremo Msdi’s Path in Pharmacy Research
September 15th 2025